Eversept Partners, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001697013

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q2 2026 · 119 positions · Total reported value $1.91B · Top-10 concentration 46.1% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 66.4% · 29 new · 41 cut · 27 exited

Active Share (vs S&P 500): 97.5% · vs QQQ: 99.8% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.9% · vs SPY -2.9% · Prev Value $1.87B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Eversept Partners, LP disclosed 119 equity positions with a combined reported value of $1.91B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 46.1% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were UTHR ($155.87M), ABVX ($121.78M), EHC ($103.80M). By sector, the heaviest allocations are Health Care 88.2%, Real Estate 5.6%. Versus the prior quarter, allocation shifted toward Health Care (+11.9pp) and away from Industrials (-0.6pp), Other (-11.8pp).

Versus the prior quarter, Eversept Partners, LP opened 29 new positions, trimmed 41 and fully exited 27, a turnover rate of 66.4% of positions. The portfolio's overlap with the prior quarter was 62% of names.

The largest new positions opened in Q2 2026 were CTRE ($43.26M), COGT ($18.97M), AMN ($13.87M).

Of the 27 positions fully exited versus the prior quarter, the largest were SPY ($69.59M), VRTX ($40.19M), TLT ($37.17M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • CTRE CARETRUST REIT INC · $43.26M
  • COGT COGENT BIOSCIENCES INC · $18.97M
  • AMN AMN HEALTHCARE · $13.87M
  • CELC CELCUITY INC · $13.38M
  • HUM HUMANA INC · $12.38M
  • CRVS CORVUS PHARMACEUTICALS I · $11.18M
  • ASND ASCENDIS PHARMA A/S · $11.10M
  • MLYS Mineralys Therapeutics, Inc. · $8.36M

Fully Exited (vs previous quarter)

  • SPY STATE STR SPDR S&P 500 ETF T · prev qtr: $69.59M
  • VRTX VERTEX PHARMACEUTICALS INC · prev qtr: $40.19M
  • TLT ISHARES TR · prev qtr: $37.17M
  • DOC HEALTHPEAK PROPERTIES INC · prev qtr: $32.55M
  • AVTR AVANTOR INC · prev qtr: $23.32M
  • HYG ISHARES TR · prev qtr: $14.32M
  • IWM ISHARES TR · prev qtr: $9.92M
  • XLK SELECT SECTOR SPDR TR · prev qtr: $9.30M

Insider Transactions (Form 4)

Latest Eversept Partners, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Eversept Partners, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 119 US equity positions with a combined value of $1.91B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-108771 (status: Approved), registered 2017-01-11
  • Regulatory AUM (Form ADV): $2.65B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 99%, registered investment companies 1%
  • Manages 3 private funds, of which 3 hedge funds
  • Website: eversept.com

Portfolio Structure

  • 119 positions · $1.91B reported value (Q2 2026)
  • Top 10 holdings = 46.1% of reported value
  • Largest position: UTHR (UNITED THERAPEUTICS CORP DEL) at 8.2%
  • Average position size: $16.06M

Sector Tilt

  • Health Care 88.2%
  • Real Estate 5.6%
  • Industrials 1.3%
  • (classified holdings cover 96% of value)

Quarterly Activity

  • Q2 2026: 29 new, 42 added, 41 reduced, 27 exited
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 88.2%
Financials 0.0%
Other 4.1%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 287.67K $155.87M 8.15%
8.15%
Add
2 913.88K $121.78M 6.37%
6.37%
Reduce
3 1.03M $103.80M 5.43%
5.43%
Add
4 602.08K $96.51M 5.05%
5.05%
Add
5 2.21M $94.95M 4.97%
4.97%
Add
6 98.60K $72.61M 3.80%
3.80%
Reduce
7 1.79M $66.45M 3.48%
3.48%
Hold
8 2.80M $61.17M 3.20%
3.20%
Reduce
9 3.40M $54.65M 2.86%
2.86%
Reduce
10 664.68K $52.70M 2.76%
2.76%
Add
11 175.81K $47.72M 2.50%
2.50%
Reduce
12 798.97K $45.39M 2.37%
2.37%
Add
13 1.07M $43.26M 2.26%
2.26%
New
14 98.25K $38.31M 2.00%
2.00%
Add
15 629.95K $36.62M 1.92%
1.92%
Reduce
16 428.65K $34.18M 1.79%
1.79%
Reduce
17 7.86M $26.27M 1.37%
1.37%
Reduce
18 481.83K $25.26M 1.32%
1.32%
Reduce
19 52.52K $24.46M 1.28%
1.28%
Add
20 20.12K $24.13M 1.26%
1.26%
Add
21 18.72M $23.96M 1.25%
1.25%
Reduce
22 602.92K $23.52M 1.23%
1.23%
Add
23 483.55K $23.06M 1.21%
1.21%
Reduce
24 148.82K $22.66M 1.19%
1.19%
Add
25 114.20K $21.36M 1.12%
1.12%
Add
26 51.15K $21.26M 1.11%
1.11%
Add
27 87.31K $19.82M 1.04%
1.04%
Reduce
28 1.25M $19.58M 1.02%
1.02%
Reduce
29 490.24K $18.97M 0.99%
0.99%
New
30 1.87M $18.66M 0.98%
0.98%
Reduce
31 80.59K $18.43M 0.96%
0.96%
Add
32 460.27K $17.01M 0.89%
0.89%
Add
33 420.64K $16.17M 0.85%
0.85%
Add
34 831.14K $15.27M 0.80%
0.80%
Add
35 249.61K $14.28M 0.75%
0.75%
Add
36 428.53K $13.87M 0.73%
0.73%
New
37 127.93K $13.38M 0.70%
0.70%
New
38 386.38K $13.36M 0.70%
0.70%
Reduce
39 3.56M $13.34M 0.70%
0.70%
Add
40 31.17K $12.38M 0.65%
0.65%
New
41 196.53K $11.86M 0.62%
0.62%
Add
42 747.99K $11.18M 0.58%
0.58%
New
43 41.62K $11.10M 0.58%
0.58%
New
44 182.89K $11.01M 0.58%
0.58%
Add
45 152.12K $10.65M 0.56%
0.56%
Reduce
46 196.30K $10.54M 0.55%
0.55%
Add
47 96.60K $10.30M 0.54%
0.54%
Add
48 217.19K $10.22M 0.53%
0.53%
Add
49 672.83K $9.52M 0.50%
0.50%
Reduce
50 275.47K $9.34M 0.49%
0.49%
Reduce

FAQ

What did Eversept Partners, LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Eversept Partners, LP reported 119 equity positions worth $1.91B in aggregate; its largest disclosed positions were UTHR ($155.87M), ABVX ($121.78M), EHC ($103.80M).

How large is Eversept Partners, LP's portfolio?

Eversept Partners, LP reported $1.91B of long equity holdings across 119 positions as of 2026-Q2. Top-10 holdings account for 46.1% of reported value.

What is Eversept Partners, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/eversept-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →